Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2016 Feb;30(1):179-91. doi: 10.1016/j.hoc.2015.09.009.

Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.

Author information

1
Department of Nuclear Medicine, Erasmus MC, University Medical Center, s-Gravendijkwal 230, Rotterdam 3015CE, The Netherlands. Electronic address: d.j.kwekkeboom@erasmusmc.nl.
2
Department of Nuclear Medicine, Erasmus MC, University Medical Center, s-Gravendijkwal 230, Rotterdam 3015CE, The Netherlands.

Abstract

Peptide receptor radionuclide therapy (PRRT) is a promising new treatment modality for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors patients. Most studies report objective response rates in 15% to 35% of patients. Progression-free (PFS) and overall survival (OS) compare favorably with that for somatostatin analogues, chemotherapy, or newer, "targeted" therapies. Prospective, randomized data regarding the potential PFS and OS benefit of PRRT compared with standard therapies is anticipated.

KEYWORDS:

Carcinoid; Neuroendocrine tumor; PRRT; Radionuclide therapy; Treatment

PMID:
26614376
DOI:
10.1016/j.hoc.2015.09.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center